# Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma

> **NCT07367685** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Second Affiliated Hospital of Fujian Medical University** · enrollment: 6 (estimated)

## Conditions studied

- Recurrent/Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** QH103 Cell Injection
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07367685
- **Lead sponsor:** The Second Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07367685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07367685, "Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07367685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*